GleamWall
中文EN

RVMD Revolution Medicines, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1628171 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-94.6%
TTM EPS YoY-75.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-93.6%
ROA-57.1%
ROIC (approx.)-84.1%
Asset turnover—

Leverage & solvency

Liabilities / assets44.2%
Debt / equity0.00x
Current ratio8.36x
Interest coverage-20.62x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-13.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$197.56M——$0$0——$0
Cost of revenue$327,000———$0———
Gross profit$197.23M———$0———
R&D expense$417.09M$394.92M$343.97M$294.94M$262.51M$224.13M$205.75M$188.10M
SG&A expense$153.29M$110.21M$101.25M$66.68M$52.76M$40.58M$35.01M$28.21M
Operating income-$373.15M-$505.13M-$445.22M-$361.63M-$315.27M-$264.71M-$240.76M-$216.31M
Interest expense$33.80M$23.78M$12.20M$11.94M$11.43M$867,000$0$0
Pretax income-$409.81M-$644.37M-$453.82M-$364.89M-$305.21M-$247.79M-$213.42M-$195.32M
Income tax-$2.35M——$0$0——-$753,000
Net income-$407.46M-$644.37M-$453.82M-$364.89M-$305.21M-$247.79M-$213.42M-$194.57M
EBITDA-$370.85M-$503.03M-$442.88M-$359.36M-$313.27M-$263.01M-$239.07M-$214.57M
EPS (basic)-1.90-3.06-2.29—-1.61-1.31-1.13—
EPS (diluted)-1.90-3.06-2.29—-1.61-1.31-1.13—
Weighted avg. shares (diluted)214.95M210.89M198.10M—189.23M188.58M188.15M—
Balance sheet
Cash & equivalents$615.91M$815.43M$440.94M$383.75M$217.44M$402.44M$333.55M$543.06M
Short-term investments$3.04B$3.12B$1.47B$1.64B$1.71B$1.73B$1.77B$1.75B
Receivables$230.72M——$0————
Inventory$11.02M——$0————
Current assets$3.98B$4.03B$1.97B$2.08B$1.98B$2.18B$2.13B$2.33B
PP&E, net$34.63M$34.61M$31.48M$33.19M$32.93M$33.05M$27.15M$24.29M
Goodwill$14.61M$14.61M$14.61M$14.61M$14.61M$14.61M$14.61M$14.61M
Intangibles$55.47M$55.80M$55.80M$55.80M$55.87M$56.14M$56.40M$56.67M
Total assets$4.30B$4.32B$2.25B$2.35B$2.25B$2.43B$2.37B$2.56B
Current liabilities$475.67M$354.06M$289.60M$290.42M$245.62M$184.53M$158.60M$163.91M
Total liabilities$1.90B$1.72B$753.82M$723.21M$655.02M$564.20M$287.20M$293.10M
Shareholders' equity$2.40B$2.61B$1.50B$1.63B$1.60B$1.87B$2.08B$2.27B
Shares outstanding216.25M214.24M200.18M197.00M189.71M186.90M186.26M185.90M
Cash flow statement
Operating cash flow-$415.65M-$387.32M-$354.17M-$274.24M-$207.31M-$221.76M-$194.44M-$138.29M
Capital expenditure$3.70M$2.29M$1.54M$1.93M$3.35M$7.45M$3.27M$1.22M
Free cash flow-$419.35M-$389.61M-$355.70M-$276.16M-$210.66M-$229.21M-$197.70M-$139.51M
Investing cash flow$80.10M-$1.66B$172.62M$74.88M$24.85M$34.28M-$15.95M-$392.90M
Financing cash flow$147.00M$2.42B$238.74M$365.66M-$1.59M$256.58M$874,000$873.80M
Depreciation & amortization$2.30M$2.10M$2.35M$2.27M$2.00M$1.70M$1.69M$1.74M
Stock-based compensation$62.15M$67.00M$87.30M$33.70M$30.78M$28.83M$25.08M$22.44M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.